Core Viewpoint - Cabaletta Bio, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $100 million to support its development of targeted cell therapies for autoimmune diseases [2][3]. Group 1: Offering Details - The offering consists of 39,200,000 shares of common stock and accompanying warrants, with an additional option for underwriters to purchase up to 15,000,000 more shares [1][2]. - The combined offering price for each share of common stock and accompanying warrant is set at $2.00, while the pre-funded warrants are priced at $1.99999 [1]. - The exercise price for the accompanying warrants is $2.50 per share, and they are immediately exercisable for fifteen months from the date of issuance [1]. Group 2: Company Overview - Cabaletta Bio is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [6]. - The company’s CABA™ platform includes strategies for engineered T cell therapies, with a lead investigational therapy called rese-cel currently in clinical trials [6]. - The RESET™ clinical development program for rese-cel spans multiple therapeutic areas, including rheumatology, neurology, and dermatology [6].